期刊文献+

吡仑帕奈单药治疗儿童局灶性癫痫的临床疗效研究 被引量:2

Clinical efficacy of perampanel monotherapy in children with focal epilepsy
原文传递
导出
摘要 目的探讨吡仑帕奈(Perampanel,PER)单药治疗在儿童局灶性癫痫的疗效及安全性。方法选取2021年1月—2022年6月在无锡市儿童医院神经内科就诊新发、既往未使用过抗癫痫发作药物的局灶性癫痫患儿46例,其中男24例、女22例,平均年龄(7.2±2.4)岁,PER单药治疗组为PER组(23例),左乙拉西坦(Levetiracetam,LEV)单药治疗组为LEV组(23例),对比两组的临床疗效及不良反应发生情况。结果3个月PER组总有效率为87.0%(20/23),LEV组总有效率为73.9%(17/23),P<0.05,差异有统计学意义;6个月PER组总有效率为78.3%(18/23),LEV组总有效率为60.9%(14/23),P<0.05,差异有统计学意义。PER组有2例患儿出现不良反应,其中嗜睡1例、头晕1例,通过暂时减少药物剂量、减慢加药速度,不良反应均消失。LEV组有3例患儿出现不良反应,均为不同程度的暴躁易怒,通过减慢加药速度,3~6个月期间2例患儿症状消失,1例患儿症状减轻。结论新型抗癫痫发作药物PER对于局灶性癫痫具有较好的抗癫痫效果,优于LEV,两种药物不良反应均较少、程度较轻,临床可酌情选择。 Objective To explore the efficacy and safety of Perampanel(PER)monotherapy in children with focal epilepsy.Methods Forty-six children with focal epilepsy who were newly diagnosed in the Department of Neurology of Wuxi Children's Hospital and had not used anti-seizure medications during January 2021 to June 2022 were selected,including 24 males and 22 females,with an average age of(7.2±2.4)years old.Mono-therapy of PER as the PER group(23 cases),mono-therapy of Levetiracetam(LEV)as the LEV group(23 cases).Compare the clinical efficacy and adverse reactions between the two groups.Result The total effective rate was 87.0%(20/23)in PER group and 73.9%(17/23)in LEV group after 3 months of treatment(P<0.05);the total effective rate in the PER group was 78.3%(18/23),and 60.9%(14/23)in the LEV group after 6 months of treatment(P<0.05).The differences were statistically significant.In the PER group,2 children had adverse reactions,1 case was lethargic,and 1 case was dizziness.By temporarily reducing the drug dose and slowing the rate of dosing,the adverse reactions disappeared.In LEV group,3 children had adverse reactions,all of who were irritable in varying degrees.By slowing down the rate of drug addition,2 children’s symptoms disappeared and 1 child's symptoms relieved during 3~6 months.Conclusion The new anti-seizure medication—PER has a better anti-epileptic effect on focal epilepsy,which is better than LEV.The adverse reactions of both drugs are less and mild,and can be selected according to clinical conditions.
作者 陈李兰 王健彪 周逸能 孙明霞 CHEN Lilan;WANG Jianbiao;ZHOU Yineng;SUN Mingxia(Department of Pediatric Neurology,Affiliated Children's Hospital of Jiangnan University(Wuxi Children’s Hospital),Wuxi 214000,China)
出处 《癫痫杂志》 2023年第3期192-194,共3页 Journal of Epilepsy
关键词 吡仑帕奈 左乙拉西坦 局灶性癫痫 Perampanel Levetiracetam Focal epilepsy
  • 相关文献

参考文献5

二级参考文献26

  • 1Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs[J]. Nat Rev Drug Discov, 2010 Jan,9(1):68-82. 被引量:1
  • 2FDA. Perampanel[OL]. FDA website, http://www.accessdata.fda.gov/ drugsat fda-docs/label/2012/2028341bl.pdf.2012-10-22/2012-11 - 1. 被引量:1
  • 3Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILATX)[J]. Epilepsy Res, 2010 Dec,92(2-3):89-124. 被引量:1
  • 4Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target[J].Epilepsy Curr, 2011 Mar,11(2):56-63. 被引量:1
  • 5Neligan A,Hauser WA, Sander JW. The epidemiology of the epilep-sies[ J]. Handb Clin Neurol, 2012, 107(3rd) : 113-33. 被引量:1
  • 6Loscher W, Schmidt D. Modern antiepileptic drug development hasfailed to deliver : ways out of the current dilemma [ J ]. Epilepsia,2011, 52(4) :657-78. 被引量:1
  • 7Rogawski MA. Revisiting AMPA receptors as an antiepileptic drugtarget[ J] . Epilepsy Curr’ 2011,11(2) ;56-63. 被引量:1
  • 8Hanada T, Hashizume Y,Tokuhara N, et al, Perampanel: a novel,orally active, noncompetitive AMPA-receptor antagonist that reducesseizure activity in rodent models of epilepsy [J] . Epilepsia,2011,52(7) :1331-1340. 被引量:1
  • 9Rogawski MA,Hanada T. Preclinical pharmacology of perampanel,aselective non-competitive AMPA receptor antagonist [ J ]. Acta NeurolScand Suppl, 2013;(197) : 19-24. 被引量:1
  • 10Satlin A,Kramer LD,Laurenza A. Development of perampanel inepilepsy[ J]. Acta Neurol Scand Suppl,2013 ; (197) :3-8. 被引量:1

共引文献21

同被引文献11

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部